Evidence map›Paper›PMID 29271381›Full record

ArticleChinese medical journal2018

Risk Factors for Carbapenem-resistant

Zhe Wang, Ran-Ran Qin, Lei Huang, Li-Ying Sun

Open access · goldAbstract read
In one paragraph

Article in Chinese medical journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 6 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 6 syntheses or guidelines pooled it, 108 citations in OpenAlex.

  1. Pooled it
  2. Risk factors for carbapenem-resistantFrontiers in public health · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Article
  10. Article
  11. Glycoconjugate Vaccines Against Nosocomial Klebsiella pneumoniae Infections.Advances in experimental medicine and biology · 2026
    Article
  12. Clinical Epidemiological Analysis of the Genotypic Spectrum and Mortality Risk in Carbapenem-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Review
  13. Article
  14. Review
  15. Article
  16. Risk factors, and outcomes of patients with carbapenem-resistantFrontiers in cellular and infection microbiology · 2025
    Article
  17. Article
  18. Article
  19. The Characterisation of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Zhe WangDepartment of Clinical Laboratory, Peking University First Hospital, Beijing 100034, China.
Ran-Ran QinGraduate School, Peking University Health Science Center, Beijing 100083, China.
Lei HuangDepartment of Clinical Laboratory, Peking University First Hospital, Beijing 100034, China.
Li-Ying SunDepartment of Clinical Laboratory, Peking University First Hospital, Beijing 100034, China.
Peking University · CNPeking University First Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKlebsiella pneumoniae (KP) is a pathogen commonly causing nosocomial infection. Carbapenem-resistant KP (CRKP) is more resistant to multiple antimicrobial drugs than carbapenem-susceptible KP (CSKP) isolates. The aim of the present study was to identify the risk factors for CRKP infection and the predictors of mortality among KP-infected adult patients.

methodsPatients with CRKP and CSKP infection were categorized as the case group and control group, respectively, and we conducted a 1:1 ratio case-control study on these groups. The CRKP isolates collected were tested for antimicrobial susceptibility and presence of KP carbapenemase (KPC) gene. Clinical data were collected to identify risk factors for CRKP infection and mortality of KP infection. Risk factors were analyzed under univariable and multivariable logistic regression model.

resultsThe independent risk factors for CRKP infection were admission to Intensive Care Unit (odds ratio [OR]: 15.486, 95% confidence interval [CI]: 3.175-75.541, P < 0.001); use of β-lactams and β-lactamase inhibitor combination (OR: 4.765, 95% CI: 1.508-15.055, P = 0.008); use of cephalosporins (OR: 8.033, 95% CI: 1.623-39.763, P = 0.011); fluoroquinolones (OR: 6.090, 95% CI: 1.343-27.613, P = 0.019); and indwelling of urethral catheter (OR: 6.164, 95% CI: 1.847-20.578, P = 0.003). However, older age (OR: 1.079, 95% CI: 1.005-1.158, P = 0.036), Charlson comorbidity index (OR: 4.690, 95% CI: 2.094-10.504, P = 0.000), and aminoglycoside use (OR: 670.252, 95% CI: 6.577-68,307.730, P = 0.006) were identified as independent risk factors for patient deaths with KP infection. The mortality of CRKP group was higher than that of the CSKP group. KPC gene did not play a role in the CRKP group. CRKP mortality was high.

conclusionImplementation of infection control measures and protection of the immunefunction are crucial.

Indexed as

AgedAged, 80 and overAnti-Bacterial Agentsbeta-Lactamase InhibitorsCarbapenemsCase-Control StudiesDrug Resistance, BacterialDrug Therapy, CombinationFemaleHumansIntensive Care UnitsKlebsiella InfectionsKlebsiella pneumoniaeLogistic ModelsMaleMiddle AgedAnti-Bacterial Agentsbeta-Lactamase InhibitorsCarbapenems

Identifiers

PMID29271381
PMCPMC5754959
OpenAlexW2782108004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.